Healthcare
Another successful short from the Bios Research team - the stock has fallen nearly 40% since they turned bearish in Feb 24. They originally identified STVN as a short due to excitement around STVN and other biologics suppliers following the tremendous growth seen in the GLP-1 craze. In Bios' opinion the market was mistakenly looking for "picks and shovels" in the GLP space and overvaluing the company. Recent earnings were disappointing and management was also forced to decrease FY24 revenue guidance. Although Bios believes STVN remains overvalued, expectations have now come down to more appropriate levels.
Edition: 187
- 31 May, 2024